|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sørlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sotiriou C and Piccart MJ: Taking
gene-expression profiling to the clinic: when will molecular
signatures become relevant to patient care? Nat Rev Cancer.
7:545–553. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Slamon DJ, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andrulis IL, Bull SB, Blackstein ME, et
al: neu/erbB-2 amplification identifies a poor-prognosis group of
women with node-negative breast cancer. Toronto Breast Cancer Study
Group. J Clin Oncol. 16:1340–1349. 1998.PubMed/NCBI
|
|
9
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hollander MC, Blumenthal GM and Dennis PA:
PTEN loss in the continuum of common cancers, rare syndromes and
mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saal LH, Gruvberger-Saal SK, Persson C, et
al: Recurrent gross mutations of the PTEN tumor suppressor gene in
breast cancers with deficient DSB repair. Nat Genet. 40:102–107.
2008. View Article : Google Scholar
|
|
12
|
Esteva FJ, Guo H, Zhang S, et al: PTEN,
PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab
response and survival in patients with HER2-positive metastatic
breast cancer. Am J Pathol. 177:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nagata Y, Lan KH, Zhou X, et al: PTEN
activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell.
6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schade B, Rao T, Dourdin N, et al: PTEN
deficiency in a luminal ErbB-2 mouse model results in dramatic
acceleration of mammary tumorigenesis and metastasis. J Biol Chem.
284:19018–19026. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Andrechek ER, Laing MA, Girgis-Gabardo AA,
Siegel PM, Cardiff RD and Muller WJ: Gene expression profiling of
neu-induced mammary tumors from transgenic mice reveals genetic and
morphological similarities to ErbB2-expressing human breast
cancers. Cancer Res. 63:4920–4926. 2003.PubMed/NCBI
|
|
17
|
Wang Q, Li SH, Wang H, et al: Concomitant
targeting of tumor cells and induction of T-cell response
synergizes to effectively inhibit trastuzumab-resistant breast
cancer. Cancer Res. 72:4417–4428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Andrechek ER, Hardy WR, Siegel PM,
Rudnicki MA, Cardiff RD and Muller WJ: Amplification of the
neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc
Natl Acad Sci USA. 97:3444–3449. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ursini-Siegel J, Rajput AB, Lu H, et al:
Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary
tumor development. Mol Cell Biol. 27:6361–6371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dourdin N, Schade B, Lesurf R, et al:
Phosphatase and tensin homologue deleted on chromosome 10
deficiency accelerates tumor induction in a mouse model of ErbB-2
mammary tumorigenesis. Cancer Res. 68:2122–2131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Q, Ding H, Liu B, et al: Addition of
the Akt inhibitor triciribine overcomes antibody resistance in
cells from ErbB2/ Neu-positive/PTEN-deficient mammary tumors. Int J
Oncol. 44:1277–1283. 2014.PubMed/NCBI
|
|
22
|
Frese KK and Tuveson DA: Maximizing mouse
cancer models. Nat Rev Cancer. 7:645–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vargo-Gogola T and Rosen JM: Modelling
breast cancer: one size does not fit all. Nat Rev Cancer.
7:659–672. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gopinathan A and Tuveson DA: The use of
GEM models for experimental cancer therapeutics. Dis Model Mech.
1:83–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sahin O, Wang Q, Brady SW, et al:
Biomarker-guided sequential targeted therapies to overcome therapy
resistance in rapidly evolving highly aggressive mammary tumors.
Cell Res. 24:542–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Berns K, Horlings HM, Hennessy BT, et al:
A functional genetic approach identifies the PI3K pathway as a
major determinant of trastuzumab resistance in breast cancer.
Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kruser TJ and Wheeler DL: Mechanisms of
resistance to HER family targeting antibodies. Exp Cell Res.
316:1083–1100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hernandez-Aya LF and Gonzalez-Angulo AM:
Targeting the phosphatidylinositol 3-kinase signaling pathway in
breast cancer. Oncologist. 16:404–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rosen LS, Ashurst HL and Chap L: Targeting
signal transduction pathways in metastatic breast cancer: a
comprehensive review. Oncologist. 15:216–235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ferris RL, Jaffee EM and Ferrone S: Tumor
antigen-targeted, monoclonal antibody-based immunotherapy: clinical
response, cellular immunity, and immunoescape. J Clin Oncol.
28:4390–4399. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park S, Jiang Z, Mortenson ED, et al: The
therapeutic effect of anti-HER2/neu antibody depends on both innate
and adaptive immunity. Cancer Cell. 18:160–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stagg J, Loi S, Divisekera U, et al:
Anti-ErbB-2 mAb therapy requires type I and II interferons and
synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad
Sci USA. 108:7142–7147. 2011. View Article : Google Scholar : PubMed/NCBI
|
